Namely, the frequency of somatic BRCA1/2 mutations is 10.94% in patients with metastatic disease (11.26% when the analysis is limited to the castration-resistant setting) and 7.18% in all patients with any stage PC. This evidence concerns the gene BRCA1 and metastatic neoplasm.